Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

blonca9
Sep 24, 2024
1 min read

CEO Neil Torbett describes the SITESEEKER target ID platform that is the company's foundation. More color on individual programs will be disclosed at the upcoming Targeted Protein Degradation & Induced Proximity Symposium in October.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight